Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 3, 2012, Pages 491-499

  Oshima, Goro ^a,b   Wennerberg, Johan ^a   Yamatodani, Takashi ^a   Kjellén, Elisabeth ^b   Mineta, Hiroyuki ^b   Johnsson, Anders ^a   Ekblad, Lars ^a  

^a LUND UNIVERSITY   (Sweden)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cetuximab; Epidermal growth factor receptor; Epigen; Head and neck squamous cell carcinoma; Prediction; TGF alpha

Indexed keywords

AMPHIREGULIN; BETACELLULIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGEN; EPIREGULIN; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLYCOPROTEIN; LIGAND; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; HEAD AND NECK CARCINOMA; IN VITRO STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SQUAMOUS CELL CARCINOMA; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; HUMAN; METABOLISM; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84859794327     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1127-5     Document Type: Article

References (28)

1. Astsaturov I, Cohen RB, Harari P (2007) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 7(7):650-665 (Pubitemid 350074968)
2. Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, Rowinsky EK, Xu LA, Harbison CT, Clark EA, Mauro DJ, Khambata-Ford S (2011) Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 104(3):488-495. doi: 10.1038/sj.bjc.6606054
3. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28(7):1254-1261. doi:10.1200/JCO.2009.24.6116
4. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-578. doi:10.1056/ NEJMoa053422 (Pubitemid 43209104)
5. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximabinduced rash and survival. Lancet Oncol 11(1):21-28. doi: 10.1016/S1470-2045(09)70311-0
6. Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ (2011) Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFRtyrosine kinase inhibitors. Cancer 117(1):143-151. doi:10.1002/ cncr.25560
7. Dempsey PJ, Coffey RJ (1994) Basolateral targeting and efficient consumption of transforming growth factor-alpha when expressed in Madin-Darby canine kidney cells. J Biol Chem 269(24):16878-16889 (Pubitemid 24200454)
8. Egloff AM, Grandis JR (2009) Improving response rates to EGFRtargeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009:896407. doi:10.1155/2009/896407
9. Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G, Ciardiello F (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA nonsmall- cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4(1):241-249 (Pubitemid 28062903)
10. Grandis JR, Chakraborty A, Zeng Q, Melhem MF, Tweardy DJ (1998a) Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 69(1):55-62. doi:10.1002/(SICI)1097- 4644 (19980401)69:1\55:AID-JCB6[3.0.CO;2-U (Pubitemid 28099922)
11. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ (1998b) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90(11):824-832 (Pubitemid 28280548)
12. Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exp Cell Res 284(1):2-13. doi:S0014482702001052 (Pubitemid 36331964)
13. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH (2010) Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5(9):e12702. doi:10.1371/ journal.pone.0012702
14. Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, Wahlberg P (2006) p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol 45(3):300-305. doi:10.1080/02841860600547380 (Pubitemid 43675571)
15. Henriksson E, Kjellen E, Baldetorp B, Bendahl PO, Borg A, Brun E, Mertens F, Ohlsson T, Rennstam K, Wennerberg J, Wahlberg P (2009) Comparison of cisplatin sensitivity and the 18F fluoro-2- deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck. J Exp Clin Cancer Res 28:17. doi:10.1186/1756-9966- 28-17
16. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Penault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27(30):5068-5074. doi:10.1200/JCO.2008.21.3744
17. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA III, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230-3237. doi:10.1200/JCO. 2006.10.5437 (Pubitemid 47325606)
18. Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, Yarden Y (2005) Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 280(9):8503-8512. doi:10.1074/jbc.M413919200 (Pubitemid 40349755)
19. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G, Mancuso S (1996) Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74(8):1253-1257 (Pubitemid 26360115)
20. Niu G, Li Z, Xie J, Le QT, Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50(7):1116-1123. doi:10.2967/jnumed.109.061820
21. O-Charoenrat P, Rhys-Evans P, Eccles S (2000) Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int J Cancer 88(5):759-765. doi:10.1002/1097- 0215(20001201)88:5\759:AID-IJC12[3.0.CO;2-0
22. Oliveras-Ferraros C, Vall-Llovera AM, Salip DC, Vazquez-Martin A, Cufi S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R, Menendez JA (2010) Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs. doi:10.1007/s10637-010-9612-2
23. Song JI, Grandis JR (2000) STAT signaling in head and neck cancer. Oncogene 19(21):2489-2495. doi:10.1038/sj.onc.1203483 (Pubitemid 30339204)
24. Tinhofer I, Klinghammer K, Weichert W, Knodler M, Stenzinger A, Gauler T, Budach V, Keilholz U (2011) Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximabdocetaxel treatment. Clin Cancer Res 17(15):5197-5204. doi: 10.1158/1078-0432.CCR-10-3338
25. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116-1127. doi:10.1056/NEJMoa0802656
26. Welinder C, Ekblad L (2011) Coomassie staining as loading control in Western blot analysis. J Proteome Res 10(3):1416-1419. doi: 10.1021/pr1011476
27. Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H, Wennerberg J (2009) Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 135(3):395-402. doi:10.1007/s00432-008-0475-2
28. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA (2008) Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 14(21):6963-6973. doi:10.1158/1078-0432.CCR-08-0957